Saturday 17 October 2026 Export TVRD’s income statement to Excel — free account

Tvardi Therapeutics, Inc.

In the quarter to June 2026, revenue grew 20.3%, EPS fell 235.3% and free cash flow fell 57.3%, each against the same quarter a year earlier.

1.01 0.06 −5.61%

Follow TVRD

Alert me

Market cap: $14.3M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 3/9
Altman Z: −5.15
Beneish M: −3.66
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 14.27

Revenue 11.12

Net Income (26.06)

Free Cash Flow (25.03)

Net Debt (15.76)

Current Ratio 1.87

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.45)

P/S ratio 0.85

P/B ratio 1.13

Past 5Y EPS Growth —

This Y EPS Growth 31.04%

Next Y EPS Growth 8.37%

Next Y revenue growth 408.06%

Next 5Y EPS Growth 1.03%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.22%

10-year low 10-year high

P/B against its own 10 years 6.33%

10-year low 10-year high

EV/Sales against its own 10 years 22.47%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	101	32	31	16
Receivables	4	4	—	—
Inventory	3	1	—	—
Other	—	—	—	—
	116	32	32	17

	2023	2024	2025	Q'26
Payables	—	2	3	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	26	10	11	9

Compound Annual Growth %

	10y	5y	3y
Sales	8.43%	(18.53%)	(32.33%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(14.89%)	(39.05%)	(49.09%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	—	—	—	—
’24	2	1	3	5	7
’23	6	7	5	3	21
’22	5	23	11	3	42
’21	2	—	20	1	23
’20	8	6	9	112	135
’19	4	5	6	5	20

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(9)	—	—	—
’25	(8)	(6)	(4)	(6)	(23)
’24	(30)	24	(7)	(5)	(18)
’23	(35)	(20)	(20)	(17)	(92)
’22	(26)	(5)	(25)	(24)	(79)
’21	(24)	(21)	(14)	(1)	(60)
’20	(38)	(28)	(22)	82	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(9)	—	—	—
’25	(8)	(6)	(4)	(6)	(23)
’24	(31)	23	(8)	(6)	(19)
’23	(35)	(20)	(20)	(19)	(94)
’22	(26)	(5)	(25)	(24)	(79)
’21	(24)	(21)	(14)	(1)	(60)
’20	(38)	(28)	(22)	82	(6)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.73)	(0.69)	—	—	—
’25	(3.22)	0.49	(0.59)	(0.78)	(2.34)
’24	(20.17)	(2.71)	(2.14)	13.67	(11.42)
’23	(17.65)	(20.89)	(18.73)	(21.25)	(78.88)
’22	(18.73)	(2.88)	(15.49)	(20.17)	(57.27)
’21	(16.93)	(21.97)	(0.72)	(22.69)	(62.67)
’20	(22.33)	(19.45)	(12.61)	57.27	6.48

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	153.36	336.60	412.56	461.88	319.68	403.92	266.40	20.45	8.14	3.74	Analyst estimates 2026–2028 Powerpack
	High	636.84	1,026.00	874.80	991.80	688.82	1,067.29	502.74	449.64	41.40	43.65
People
People	Employees	34	37	55	67	80	84	106	55	10	12
	Revenue/emp, $m	0.00	0.02	0.24	0.30	1.69	0.27	0.39	0.38	0.71	0.00
Income, $m
Income, $m	Revenue	0	1	13	20	135	23	42	21	7	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	82.65	70.56	91.31	—
	EBT	(58)	(58)	(74)	(107)	8	(88)	(85)	(119)	(29)	(18)
	EBT margin, %	(67,148.84)	(6,402.74)	(552.39)	(539.02)	5.71	(384.06)	(204.16)	(565.21)	(411.90)	0.00
	Net income	(57)	(58)	(74)	(106)	8	(88)	(85)	(119)	(29)	(18)
	Depreciation	1	0	(1)	(1)	1	2	2	2	0	0
Per share, $
Per share, $	Revenue	0.11	1.05	13.52	16.79	102.61	16.35	28.09	13.94	2.77	0.00
	Earnings	(75.64)	(66.99)	(74.20)	(89.68)	6.48	(62.67)	(57.27)	(78.88)	(11.42)	(2.46)
	Cash flow	(62.56)	(63.29)	(22.38)	(92.20)	(4.17)	(42.67)	(52.83)	(61.23)	(7.11)	(3.17)
	Capex	(0.95)	(0.02)	(0.07)	(0.02)	(0.27)	0.02	(0.03)	(1.58)	(0.41)	0.00
	Free cash flow	(63.50)	(63.31)	(22.45)	(92.21)	(4.43)	(42.65)	(52.86)	(62.81)	(7.52)	(3.17)
	Book value	66.97	100.17	134.10	157.60	189.15	161.57	106.55	37.96	(35.40)	2.82
	Shares, m	1	1	1	1	1	1	1	2	3	7
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	168.01	0.00	0.00	0.00	0.00	—
	P/S	3,094.42	401.64	32.43	34.55	5.31	4.57	14.03	1.95	4.42	—
	P/B	5.25	4.61	3.49	3.68	2.88	2.71	3.70	0.72	0.00	—
	EV/Sales	2,408.65	308.80	23.22	28.40	4.21	3.56	11.26	(1.15)	7.03	—
	EV/FCF	(4.31)	(5.61)	(14.92)	(5.17)	(97.50)	(8.02)	(5.98)	0.26	(3.50)	—
Cash, $m
Cash, $m	Operating cash flow	(47)	(55)	(22)	(109)	(5)	(60)	(79)	(92)	(18)	(23)
	Capex	(1)	0	0	0	0	0	0	(2)	(1)	—
	Free cash flow	(48)	(55)	(22)	(109)	(6)	(60)	(79)	(94)	(19)	(23)
Balance, $m
Balance, $m	Working capital	50	87	128	123	177	156	145	91	21	20
	Total debt	—	—	—	3	4	2	2	—	30	—
	Net debt	(59)	(93)	(162)	(152)	(177)	(165)	(146)	(101)	(1)	(31)
	Shareholders’ equity	51	87	134	187	249	228	159	57	(91)	21
Returns, %
Returns, %	ROA	(65.57)	(72.28)	(51.43)	(50.20)	3.34	(34.13)	(39.82)	(76.94)	(36.51)	(54.15)
	ROIC	0.00	0.00	0.00	(199.09)	4.69	(89.22)	(421.75)	0.00	0.00	0.00
	ROE	(73.54)	(84.54)	(67.16)	(66.41)	3.86	(37.12)	(44.25)	(109.80)	172.69	51.90

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Mar 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DARE Dare Bioscience, Inc.	$14.6M	— (loss-making)	— (loss-making)	+984.43% (above 0%: growing)	n/m	−30.23% (below 0%: shrinking)	(70.56%)	(1,582.93%)	Compare
ADAPY Adaptimmune Therapeutics PLC	$14.6M	— (loss-making)	— (loss-making)	−89.33% (below 0%: shrinking)	n/m	−174.72% (below 0%: shrinking)	81.71%	(221.45%)	Compare
TVRD Tvardi Therapeutics, Inc.	$14.3M	— (loss-making)	— (loss-making)	+20.33% (above 0%: growing)	n/m	−57.26% (below 0%: shrinking)	100.00%	0.00%
CNSY Cerenome, Inc.	$14.3M	— (loss-making)	— (loss-making)	−70.43% (below 0%: shrinking)	n/m	−31.46% (below 0%: shrinking)	100.00%	(2,203.65%)	Compare
CLVSQ Clovis Oncology, Inc.	$14.2M	— (loss-making)	— (loss-making)	−19.13% (below 0%: shrinking)	n/m	+11.83% (above 0%: growing)	71.93%	(144.26%)	Compare
BCDA BioCardia, Inc.	$14.2M	— (loss-making)	— (loss-making)	−93.02% (below 0%: shrinking)	n/m	−5.15% (below 0%: shrinking)	100.00%	0.00%	Compare
RVLP RVL Pharmaceuticals PLC	$14.1M	— (loss-making)	— (loss-making)	−2.25% (below 0%: shrinking)	n/m	−734.24% (below 0%: shrinking)	76.43%	(266.66%)	Compare
LPCN Lipocine Inc.	$13.9M	— (loss-making)	— (loss-making)	−69.48% (below 0%: shrinking)	n/m	−60.56% (below 0%: shrinking)	100.00%	(1,495.11%)	Compare
KTTA Pasithea Therapeutics Corp.	$13.7M	— (loss-making)	— (loss-making)	+1,494.04% (above 0%: growing)	n/m	−21.68% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$14.2M	—	—	−44.30%	—	−30.84%	79.07%	(244.05%)

All 614 Biotechnology stocks →

Tvardi Therapeutics, Inc. (TVRD) key facts

Tvardi Therapeutics, Inc. (TVRD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TVRD traded at $1.01, a market capitalization of $14.3 million.
Return on equity was 51.9% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −5.15 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.